On the public citation graph
Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors
0 signed · 591 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/archderm.138.1.129openalex-snapshot
Follicular Toxic Effects of Chimeric Anti–Epidermal Growth Factor Receptor Antibody Cetuximab Used to Treat Human Solid Tumors
inferredcites →https://doi.org/10.1001/jama.290.16.2149openalex-snapshot
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer
inferredcites →https://doi.org/10.1002/j.1460-2075.1995.tb00206.xopenalex-snapshot
Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure.
inferredcites →https://doi.org/10.1016/j.ijrobp.2003.09.098openalex-snapshot
Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody
inferredcites →https://doi.org/10.1016/s0002-9440(10)63654-1openalex-snapshot
Blockade of the EGF Receptor Induces a Deranged Chemokine Expression in Keratinocytes Leading to Enhanced Skin Inflammation
inferredcites →https://doi.org/10.1016/s0733-8635(05)70237-0openalex-snapshot
SYSTEMIC RETINOID THERAPY
inferredcites →https://doi.org/10.1016/s1359-6349(04)80287-8openalex-snapshot
279 Correlation of acne rash and tumor response with cetuximab monotherapy in patients with colorectal cancer refractory to both irinotecan and oxaliplatin
inferredcites →https://doi.org/10.1038/sj.bjc.6603055openalex-snapshot
Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer
inferredcites →https://doi.org/10.1038/sj.onc.1203778openalex-snapshot
Constitutive expression of erbB2 in epidermis of transgenic mice results in epidermal hyperproliferation and spontaneous skin tumor development
inferredcites →https://doi.org/10.1046/j.1365-2133.2001.04226.xopenalex-snapshot
Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225
inferredcites →https://doi.org/10.1046/j.1365-2133.2002.04864.xopenalex-snapshot
Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor
inferredcites →https://doi.org/10.1046/j.1523-1747.1998.00393.xopenalex-snapshot
Retinoids Downregulate Vascular Endothelial Growth Factor/Vascular Permeability Factor Production by Normal Human Keratinocytes
inferredcites →https://doi.org/10.1056/nejmoa033025openalex-snapshot
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
inferredcites →https://doi.org/10.1067/mjd.2001.117520openalex-snapshot
Reversible agranulocytosis associated with oral terbinafine in a pediatric patient
inferredcites →https://doi.org/10.1067/mjd.2002.124621openalex-snapshot
Paronychia induced by cetuximab, an antiepidermal growth factor receptor antibody
inferredcites →https://doi.org/10.1074/jbc.274.52.37285openalex-snapshot
Activation of Epidermal Growth Factor Receptor Promotes Late Terminal Differentiation of Cell-Matrix Interaction-disrupted Keratinocytes
inferredcites →https://doi.org/10.1080/00015550310005898openalex-snapshot
Cutaneous Side Effects in Non-Small Cell Lung Cancer Patients Treated with Iressa (ZD1839), an Inhibitor of Epidermal Growth Factor
inferredcites →https://doi.org/10.1080/000155599750009834openalex-snapshot
Increased Expression of Vascular Endothelial Growth Factor in Pyogenic Granulomas
inferredcites →https://doi.org/10.1080/02841860310006038openalex-snapshot
Epidermal Growth Factor Receptor Inhibition Induces Trichomegaly
inferredcites →https://doi.org/10.1093/annonc/mdh257openalex-snapshot
Pharmacological background of EGFR targeting
inferredcites →https://doi.org/10.1093/annonc/mdi157openalex-snapshot
Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer
inferredcites →https://doi.org/10.1111/1523-1747.ep12276708openalex-snapshot
Differences in Human Skin Between the Epidermal Growth Factor Receptor Distribution Detected by EGF Binding and Monoclonal Antibody Recognition
inferredcites →https://doi.org/10.1111/j.1346-8138.2003.tb00387.xopenalex-snapshot
Paronychia Induced by Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
inferredcites →https://doi.org/10.1111/j.1365-2133.2004.06026.xopenalex-snapshot
Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours
inferredcites →https://doi.org/10.1111/j.1365-2133.2004.06265.xopenalex-snapshot
Trichomegaly following treatment with gefitinib (ZD1839)
inferredcites →https://doi.org/10.1111/j.1365-2230.1986.tb00439.xopenalex-snapshot
Etretinate and the nails (study of 130 cases) possible mechanisms of some side-effects
inferredcites →https://doi.org/10.1111/j.1365-2230.2004.01466.xopenalex-snapshot
Acneiform lesions secondary to ZD1839, an inhibitor of the epidermal growth factor receptor
inferredcites →https://doi.org/10.1126/science.7618084openalex-snapshot
Targeted Disruption of Mouse EGF receptor: Effect of Genetic Background on Mutant Phenotype
inferredcites →https://doi.org/10.1158/0008-5472.can-04-1036openalex-snapshot
An Epidermal Growth Factor Receptor Intron 1 Polymorphism Mediates Response to Epidermal Growth Factor Receptor Inhibitors
inferredcites →https://doi.org/10.1159/000073100openalex-snapshot
Development of Multiple Paronychia and Periungual Granulation in Patients Treated with Gefitinib, an Inhibitor of Epidermal Growth Factor Receptor
inferredcites →https://doi.org/10.1159/000078818openalex-snapshot
New Advances on the Functions of Epidermal Growth Factor Receptor and Ceramides in Skin Cell Differentiation, Disorders and Cancers
inferredcites →https://doi.org/10.1159/000223954openalex-snapshot
Über das Mikrokarzinom am Colium uteri
inferredcites →https://doi.org/10.1200/jco.20.1.110openalex-snapshot
Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor Inhibition
inferredcites →https://doi.org/10.1200/jco.20.3.719openalex-snapshot
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
inferredcites →https://doi.org/10.1200/jco.2000.18.4.904openalex-snapshot
Phase I Studies of Anti–Epidermal Growth Factor Receptor Chimeric Antibody C225 Alone and in Combination With Cisplatin
inferredcites →https://doi.org/10.1200/jco.2001.19.13.3267openalex-snapshot
Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies
inferredcites →https://doi.org/10.1200/jco.2002.03.100openalex-snapshot
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types
inferredcites →https://doi.org/10.1200/jco.2002.10.112openalex-snapshot
ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial
inferredcites →https://doi.org/10.1200/jco.2004.02.168openalex-snapshot
Complications of Therapy in Cancer Patients
inferredcites →https://doi.org/10.1200/jco.2004.05.114openalex-snapshot
Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor Receptor
inferredcites →https://doi.org/10.1200/jco.2004.06.075openalex-snapshot
Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
inferredcites →https://doi.org/10.1200/jco.2004.08.189openalex-snapshot
Evaluation of Biologic End Points and Pharmacokinetics in Patients With Metastatic Breast Cancer After Treatment With Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
inferredcites →https://doi.org/10.1200/jco.2004.10.182openalex-snapshot
Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor
inferredcites →https://doi.org/10.1200/jco.2004.11.057openalex-snapshot
Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1200/jco.2004.11.061openalex-snapshot
Safety, Pharmacokinetics, and Activity of ABX-EGF, a Fully Human Anti–Epidermal Growth Factor Receptor Monoclonal Antibody in Patients With Metastatic Renal Cell Cancer
inferredcites →https://doi.org/10.1200/jco.2004.22.14_suppl.7100openalex-snapshot
Management of cutaneous adverse effects during treatment with ZD1839 in advanced non-small cell lung cancer (NSCLC): Surprising efficacy of early local treatment
inferredcites →https://doi.org/10.1200/jco.2005.04.057openalex-snapshot
Practical Management of Patients With Non–Small-Cell Lung Cancer Treated With Gefitinib
inferredcites →https://doi.org/10.3816/clc.2003.n.016openalex-snapshot
Dermatologic Side Effects Associated with Gefitinib Therapy: Clinical Experience and Management
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.1001/archderm.142.7.939-aopenalex-snapshot
Gefitinib: A Cause of Pyogenic Granulomalike Lesions of the Nail
inferred← citeshttps://doi.org/10.1001/archderm.143.7.889openalex-snapshot
Treatment of Recurrent Squamous Cell Carcinoma of the Skin With Cetuximab
inferred← citeshttps://doi.org/10.1001/archdermatol.2007.57openalex-snapshot
Baboon Syndrome Induced by Cetuximab
inferred← citeshttps://doi.org/10.1001/archdermatol.2011.719openalex-snapshot
Economic Burden of Dermatologic Adverse Events Induced by Molecularly Targeted Cancer Agents
inferred← citeshttps://doi.org/10.1001/archdermatol.2012.3022openalex-snapshot
Gefitinib-Induced Paronychia
inferred← citeshttps://doi.org/10.1001/jamadermatol.2022.0725openalex-snapshot
Usefulness of Noninvasive Management With the Gutter Method for Epidermal Growth Factor Receptor Inhibitor–Induced Paronychia, Pyogenic Granuloma–Like Lesion, and Ingrown Nail
inferred← citeshttps://doi.org/10.1001/jamadermatol.2026.1161openalex-snapshot
Ecthymalike Ulcerations in Patients With Lung Cancer Treated With Combined Amivantamab and Osimertinib
inferred← citeshttps://doi.org/10.1002/9781118590638.ch10openalex-snapshot
Hair Disorders Associated with Anticancer Agents
inferred← citeshttps://doi.org/10.1002/9781118590638.ch17openalex-snapshot
Epidermal Growth Factor Receptor Inhibitor Reactions
inferred← citeshttps://doi.org/10.1002/9781118590638.ch33openalex-snapshot
Management Algorithms for Dermatologic Adverse Events
inferred← citeshttps://doi.org/10.1002/9781118590638.ch34openalex-snapshot
Dermatologic Therapeutics and Formulations
inferred← citeshttps://doi.org/10.1002/9781118590638.ch35openalex-snapshot
Dermatologic Techniques and Procedures
inferred← citeshttps://doi.org/10.1002/9781118590638.ch4openalex-snapshot
Types of Dermatologic Reactions
inferred← citeshttps://doi.org/10.1002/9781119709268.rook091openalex-snapshot
Acquired Non‐Infective Disorders of the Pilosebaceous Unit
inferred← citeshttps://doi.org/10.1002/9783527673643.ch15openalex-snapshot
Introduction to Kinase Antitargets
inferred← citeshttps://doi.org/10.1002/cncr.23442openalex-snapshot
Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum‐based therapies
inferred← citeshttps://doi.org/10.1002/cncr.25090openalex-snapshot
Effects of epidermal growth factor receptor inhibitor‐induced dermatologic toxicities on quality of life
inferred← citeshttps://doi.org/10.1002/jmv.28518openalex-snapshot
Delayed cutaneous hypersensitivity reactions following the use of infliximab or adalimumab in patients with coronavirus disease 2019
inferred← citeshttps://doi.org/10.1002/lsm.23080openalex-snapshot
Pulsed‐dye laser as an adjuvant treatment for papulopustular eruptions from epidermal growth factor receptor inhibitors, a randomized blinded split‐faced controlled trial
inferred← citeshttps://doi.org/10.1002/nur.21722openalex-snapshot
“I Lost My Image, the Image Others Know Me By”: Findings From a Hermeneutic Phenomenological Study of Patients Living With Treatment-Induced Cutaneous Toxicities
inferred← citeshttps://doi.org/10.1007/978-0-85729-787-7_4openalex-snapshot
Gastrointestinal Cancer: Selection of Clinically Relevant Drug-Induced Toxicities Encountered in Gastrointestinal Cancer Treatment
inferred← citeshttps://doi.org/10.1007/978-1-4020-8767-7openalex-snapshot
Pathogenesis and Clinical Practice in Gastroenterology
inferred← citeshttps://doi.org/10.1007/978-1-4020-9591-7_23openalex-snapshot
Progress in the treatment of colorectal cancer: the impact of new drugs
inferred← citeshttps://doi.org/10.1007/978-1-4614-5438-0openalex-snapshot
Pathobiology of Cancer Regimen-Related Toxicities
inferred← citeshttps://doi.org/10.1007/978-1-4614-8344-1_54openalex-snapshot
Drug-Induced Acneiform Eruptions
inferred← citeshttps://doi.org/10.1007/978-1-4614-8815-6_4openalex-snapshot
EGFR Inhibitors as Therapeutic Agents in Head and Neck Cancer
inferred← citeshttps://doi.org/10.1007/978-2-287-72092-5_24openalex-snapshot
Effets cutanéo-muqueux indésirables des cytokines et des nouvelles molécules anticancéreuses
inferred← citeshttps://doi.org/10.1007/978-2-8178-0527-6_11openalex-snapshot
Indications et prise en charge des effets secondaires des biothérapies anti-EGFR
inferred← citeshttps://doi.org/10.1007/978-3-030-23765-3_1openalex-snapshot
Current Development of Monoclonal Antibodies in Cancer Therapy
inferred← citeshttps://doi.org/10.1007/978-3-030-35820-4_16openalex-snapshot
Adverse Cutaneous Reactions to Chemotherapeutic Agents
inferred← citeshttps://doi.org/10.1007/978-3-030-68334-4_6openalex-snapshot
Conventional Chemotherapy Versus Targeted Therapy
inferred← citeshttps://doi.org/10.1007/978-3-030-80962-1_257-1openalex-snapshot
Target Hyperactive ERK Signaling for Cancer Therapy
inferred← citeshttps://doi.org/10.1007/978-3-031-09388-3_25openalex-snapshot
Cutaneous Reactions to Oncologic Targeted Therapy
inferred← citeshttps://doi.org/10.1007/978-3-031-42859-3_13openalex-snapshot
Macrolides in Chronic Skin Disorders
inferred← citeshttps://doi.org/10.1007/978-3-031-53888-9_57-1openalex-snapshot
Benign Vascular Lesions
inferred← citeshttps://doi.org/10.1007/978-3-032-00771-1_257openalex-snapshot
Target Hyperactive ERK Signaling for Cancer Therapy
inferred← citeshttps://doi.org/10.1007/978-3-319-66200-8_8openalex-snapshot
Cutaneous Reactions to Targeted Anticancer Agents
inferred← citeshttps://doi.org/10.1007/978-3-319-70253-7_4openalex-snapshot
Gastrointestinal Cancer: Selection of Clinically Relevant Drug-Induced Toxicities Encountered in Gastrointestinal Cancer Treatment
inferred← citeshttps://doi.org/10.1007/978-3-319-90990-5_37openalex-snapshot
Dermatologic Adverse Events
inferred← citeshttps://doi.org/10.1007/978-3-319-92306-2_8openalex-snapshot
Pyogenic Granuloma (Lobular Capillary Hemangioma)
inferred← citeshttps://doi.org/10.1007/978-88-470-1806-8_16openalex-snapshot
Tossicità acuta da trattamento: terapia di supporto
inferred← citeshttps://doi.org/10.1007/978-90-481-2289-9_10openalex-snapshot
Monoclonal antibody therapy
inferred← citeshttps://doi.org/10.1007/s00018-014-1751-8openalex-snapshot
A new prodrug form of Affibody molecules (pro-Affibody) is selectively activated by cancer-associated proteases
inferred← citeshttps://doi.org/10.1007/s00105-010-1943-6openalex-snapshot
Therapie mit Inhibitoren des epidermalen Wachstumsfaktorrezeptors
inferred← citeshttps://doi.org/10.1007/s00280-013-2370-zopenalex-snapshot
A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study
inferred← citeshttps://doi.org/10.1007/s00280-016-3154-zopenalex-snapshot
Phase I study of the second-generation, recombinant, human EGFR antibody necitumumab in Japanese patients with advanced solid tumors
inferred← citeshttps://doi.org/10.1007/s00280-020-04228-4openalex-snapshot
Correlations between serum cetuximab and EGFR-related markers, and skin disorders in head and neck cancer patients
inferred← citeshttps://doi.org/10.1007/s00403-008-0853-2openalex-snapshot
Regeneration of human epidermis on acellular dermis is impeded by small-molecule inhibitors of EGF receptor tyrosine kinase
inferred← citeshttps://doi.org/10.1007/s00432-011-1061-6openalex-snapshot
First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer
inferred← citeshttps://doi.org/10.1007/s00520-009-0744-xopenalex-snapshot
A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group
inferred← citeshttps://doi.org/10.1007/s00520-011-1110-3openalex-snapshot
Trolamine emulsion for the prevention of radiation dermatitis in patients with squamous cell carcinoma of the head and neck
inferred← citeshttps://doi.org/10.1007/s00520-011-1197-6openalex-snapshot
Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities
inferred← citeshttps://doi.org/10.1007/s00520-012-1404-0openalex-snapshot
Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors
inferred← citeshttps://doi.org/10.1007/s00520-014-2466-yopenalex-snapshot
Increased rates of local complication of central venous catheters in the targeted anticancer therapy era: a 2-year retrospective analysis
inferred← citeshttps://doi.org/10.1007/s00520-016-3254-7openalex-snapshot
Mechanisms of skin aging induced by EGFR inhibitors
inferred← citeshttps://doi.org/10.1007/s00520-016-3419-4openalex-snapshot
Dermatologic events from EGFR inhibitors: the issue of the missing patient voice
inferred← citeshttps://doi.org/10.1007/s00520-020-05765-7openalex-snapshot
Results of the non-small cell lung cancer part of a phase III, open-label, randomized trial evaluating topical corticosteroid therapy for facial acneiform dermatitis induced by EGFR inhibitors: stepwise rank down from potent corticosteroid (FAEISS study, NCCH-1512)
inferred← citeshttps://doi.org/10.1007/s00520-022-07254-5openalex-snapshot
A phase 2 study for evaluating doxycycline 50 mg once daily and 100 mg once daily as preemptive treatment for skin toxicity in patients with metastatic colorectal cancer treated with an anti-EGFR and chemotherapy
inferred← citeshttps://doi.org/10.1007/s00761-008-1548-1openalex-snapshot
Haut- und Schleimhauttoxizität neuer Substanzen
inferred← citeshttps://doi.org/10.1007/s10147-016-0980-2openalex-snapshot
Approving molecularly targeted drugs: different approval processes for cytotoxic agents
inferred← citeshttps://doi.org/10.1007/s10269-006-0534-8openalex-snapshot
Toxicité cutanée des anti-EGF-R
inferred← citeshttps://doi.org/10.1007/s10637-010-9567-3openalex-snapshot
Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886)
inferred← citeshttps://doi.org/10.1007/s10637-014-0128-zopenalex-snapshot
The efficacy of Pistacia Terebinthus soap in the treatment of cetuximab-induced skin toxicity
inferred← citeshttps://doi.org/10.1007/s10989-021-10223-xopenalex-snapshot
Rational Molecular Profiling of Receptor-Associated Late Transducer Peptide Selectivity Across Her/Rtk Kinases
inferred← citeshttps://doi.org/10.1007/s11136-019-02133-9openalex-snapshot
A pilot study on aesthetic treatments performed by qualified aesthetic practitioners: efficacy on health-related quality of life in breast cancer patients
inferred← citeshttps://doi.org/10.1007/s11307-011-0503-5openalex-snapshot
High Vascular Delivery of EGF, but Low Receptor Binding Rate Is Observed in AsPC-1 Tumors as Compared to Normal Pancreas
inferred← citeshttps://doi.org/10.1007/s11523-006-0013-6openalex-snapshot
Folliculitis and perionyxis associated with the EGFR inhibitor erlotinib
inferred← citeshttps://doi.org/10.1007/s11523-008-0092-7openalex-snapshot
Management of skin toxicity of epidermal growth factor receptor inhibitors
inferred← citeshttps://doi.org/10.1007/s11523-009-0114-0openalex-snapshot
Skin toxicities associated with epidermal growth factor receptor inhibitors
inferred← citeshttps://doi.org/10.1007/s11845-009-0458-6openalex-snapshot
Triad of trichomegaly, alopecia and male-pattern hair growth during treatment with erlotinib in non-small-cell lung cancer
inferred← citeshttps://doi.org/10.1007/s11864-013-0254-4openalex-snapshot
Dermatologic Adverse Events to Targeted Therapies in Lower GI Cancers: Clinical Presentation and Management
inferred← citeshttps://doi.org/10.1007/s11888-006-0031-xopenalex-snapshot
Targeted therapies in colorectal cancer: Complications and management
inferred← citeshttps://doi.org/10.1007/s11888-013-0174-5openalex-snapshot
Management of Toxicity Induced by Anti-EGFR Therapy in Metastatic Colorectal Cancer
inferred← citeshttps://doi.org/10.1007/s12094-010-0595-4openalex-snapshot
Different patterns of toxicity after sequential administration of two anti-EGFR monoclonal antibodies
inferred← citeshttps://doi.org/10.1007/s13555-016-0163-0openalex-snapshot
Cutaneous Side Effects and Transepidermal Water Loss To Gefitinib: A Study of 11 Patients
inferred← citeshttps://doi.org/10.1007/s13555-022-00739-5openalex-snapshot
Perifollicular Xanthoma Occurring in Patients after Erlotinib Treatment
inferred← citeshttps://doi.org/10.1007/s13671-016-0130-0openalex-snapshot
Cutaneous Manifestations of Chemotherapeutic Drugs
inferred← citeshttps://doi.org/10.1007/s13671-023-00413-9openalex-snapshot
Inpatient Evaluation and Management of Generalized Pustular Dermatoses
inferred← citeshttps://doi.org/10.1007/s40257-017-0256-2openalex-snapshot
Review and Management of Acneiform Eruptions in Patients with Immune Disorders
inferred← citeshttps://doi.org/10.1007/s40257-017-0296-7openalex-snapshot
Clinical Signs, Pathophysiology and Management of Cutaneous Side Effects of Anti-Tumor Necrosis Factor Agents
inferred← citeshttps://doi.org/10.1007/s40257-018-0378-1openalex-snapshot
Alopecia in Association with Malignancy: A Review
inferred← citeshttps://doi.org/10.1007/s40264-015-0285-9openalex-snapshot
Chimeric Fusion Proteins Used for Therapy: Indications, Mechanisms, and Safety
inferred← citeshttps://doi.org/10.1007/s40291-015-0132-9openalex-snapshot
CA-SSR1 Polymorphism in Intron 1 of the EGFR Gene in Patients with Malignant Tumors Who Develop Acneiform Rash Associated with the Use of Cetuximab
inferred← citeshttps://doi.org/10.1007/s40487-017-0050-6openalex-snapshot
EGFR Inhibitors and Cutaneous Complications: A Practical Approach to Management
inferred← citeshttps://doi.org/10.1016/b978-0-323-07154-3.00030-6openalex-snapshot
Acne and acneiform eruptions
inferred← citeshttps://doi.org/10.1016/b978-0-323-47674-4.00041-4openalex-snapshot
Dermatologic Toxicities of Anticancer Therapy
inferred← citeshttps://doi.org/10.1016/b978-0-323-48551-7.00006-7openalex-snapshot
Cutaneous Reactions to Drugs
inferred← citeshttps://doi.org/10.1016/b978-0-323-52357-8.00049-4openalex-snapshot
Management of Toxicities of Targeted Therapies
inferred← citeshttps://doi.org/10.1016/b978-0-323-61211-1.00037-1openalex-snapshot
Systemic Anticancer Agents
inferred← citeshttps://doi.org/10.1016/b978-0-444-53856-7.00002-6openalex-snapshot
Integumentary System
inferred← citeshttps://doi.org/10.1016/b978-044452771-4/50003-1openalex-snapshot
Integumentary System
inferred← citeshttps://doi.org/10.1016/b978-1-4377-1015-1.00012-6openalex-snapshot
Management of treatment-related dermatologic adverse effects
inferred← citeshttps://doi.org/10.1016/b978-1-4377-2003-7.00033-9openalex-snapshot
Systemic anticancer agents
inferred← citeshttps://doi.org/10.1016/b978-1-4557-2865-7.00044-8openalex-snapshot
Dermatologic Toxicities of Anticancer Therapy
inferred← citeshttps://doi.org/10.1016/j.actpha.2015.10.005openalex-snapshot
Les anticorps monoclonaux
inferred← citeshttps://doi.org/10.1016/j.ad.2015.01.006openalex-snapshot
Factores predictores de respuesta y revisión de la toxicidad cutánea de cetuximab y panitumumab en 116 pacientes
inferred← citeshttps://doi.org/10.1016/j.ad.2017.08.015openalex-snapshot
Inflamación de queratosis actínicas durante el tratamiento con panitumumab
inferred← citeshttps://doi.org/10.1016/j.adengl.2015.05.014openalex-snapshot
Predictors of Tumor Response to Cetuximab and Panitumumab in 116 Patients and a Review of Approaches to Managing Skin Toxicity
inferred← citeshttps://doi.org/10.1016/j.adengl.2018.07.005openalex-snapshot
Inflammation of Actinic Keratosis During Panitumumab Therapy
inferred← citeshttps://doi.org/10.1016/j.annder.2010.03.012openalex-snapshot
Intérêt de la corticothérapie locale dans le traitement des paronychies aseptiques induites par les inhibiteurs de croissance épidermique
inferred← citeshttps://doi.org/10.1016/j.annder.2013.01.442openalex-snapshot
Anomalies pigmentaires induites par les traitements anticancéreux. Deuxième partie : les thérapies ciblées
inferred← citeshttps://doi.org/10.1016/j.bmc.2018.02.022openalex-snapshot
Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors
inferred← citeshttps://doi.org/10.1016/j.bpg.2007.10.020openalex-snapshot
The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer
inferred← citeshttps://doi.org/10.1016/j.canrad.2012.05.007openalex-snapshot
Évaluation et prise en charge de la toxicité cutanée en cours de radiothérapie
inferred← citeshttps://doi.org/10.1016/j.cct.2008.01.004openalex-snapshot
Validation of treatment induced specific adverse effect as a predictor of treatment benefit: A case study of NCIC CTG BR21
inferred← citeshttps://doi.org/10.1016/j.cgh.2007.04.014openalex-snapshot
Fulminant Hepatic Failure Secondary to Erlotinib
inferred← citeshttps://doi.org/10.1016/j.clbc.2014.09.003openalex-snapshot
Papulopustular Acneiform Eruptions Resulting From Trastuzumab, a HER2 Inhibitor
inferred← citeshttps://doi.org/10.1016/j.clcc.2011.06.010openalex-snapshot
Panitumumab in Combination With Cytotoxic Chemotherapy for the Treatment of Metastatic Colorectal Carcinoma
inferred← citeshttps://doi.org/10.1016/j.clcc.2017.12.004openalex-snapshot
Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review
inferred← citeshttps://doi.org/10.1016/j.clcc.2020.01.001openalex-snapshot
Management of EGFR Inhibitor-induced Skin Toxicity and Factors Impacting Patients’ Adherence to Skin Toxicity Treatment: Health Care Provider and Patient Surveys in European Oncology Centers
inferred← citeshttps://doi.org/10.1016/j.clindermatol.2013.05.023openalex-snapshot
Acneiform eruptions
inferred← citeshttps://doi.org/10.1016/j.clindermatol.2013.06.018openalex-snapshot
Nail abnormalities associated with systemic pathologies
inferred← citeshttps://doi.org/10.1016/j.clinthera.2008.01.014openalex-snapshot
Panitumumab: Human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer
inferred← citeshttps://doi.org/10.1016/j.cllc.2017.02.002openalex-snapshot
An Open-Label, Randomized, Controlled Phase II Study of Paclitaxel-Carboplatin Chemotherapy With Necitumumab Versus Paclitaxel-Carboplatin Alone in First-Line Treatment of Patients With Stage IV Squamous Non–Small-Cell Lung Cancer
inferred← citeshttps://doi.org/10.1016/j.clon.2013.10.007openalex-snapshot
Panitumumab Monotherapy as a Second-line Treatment in Metastasised Colorectal Cancer: A Single Centre Experience
inferred← citeshttps://doi.org/10.1016/j.coi.2008.05.012openalex-snapshot
Effector mechanisms of therapeutic antibodies against ErbB receptors
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2009.07.005openalex-snapshot
Improving disease control in advanced colorectal cancer: Panitumumab and cetuximab
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2017.03.032openalex-snapshot
Management of adverse events during treatment of gastrointestinal cancers with epidermal growth factor inhibitors
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2021.103424openalex-snapshot
Cetuximab in locally advanced head and neck squamous cell carcinoma: Biological mechanisms involved in efficacy, toxicity and resistance
inferred← citeshttps://doi.org/10.1016/j.ctrv.2011.09.004openalex-snapshot
Recommendations on management of EGFR inhibitor-induced skin toxicity: A systematic review
inferred← citeshttps://doi.org/10.1016/j.det.2007.08.003openalex-snapshot
Malignancy and Cancer Treatment-Related Hair and Nail Changes
inferred← citeshttps://doi.org/10.1016/j.det.2007.08.006openalex-snapshot
Cutaneous Reactions to Chemotherapy: Commonly Seen, Less Described, Little Understood
inferred← citeshttps://doi.org/10.1016/j.det.2007.08.010openalex-snapshot
Cutaneous Reactions Related to Systemic Immunomodulators and Targeted Therapeutics
inferred← citeshttps://doi.org/10.1016/j.dsi.2011.02.003openalex-snapshot
Skin manifestations of gefitinib and the association with survival of advanced non-small-cell lung cancer in Taiwan
inferred← citeshttps://doi.org/10.1016/j.ejca.2006.11.016openalex-snapshot
Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors
inferred← citeshttps://doi.org/10.1016/j.ejca.2010.03.008openalex-snapshot
Inter-observer agreement between dermatologists and oncologists in assessing dermatological toxicities in patients with metastatic colorectal cancer treated by cetuximab-based chemotherapies: A pilot comparative study
inferred← citeshttps://doi.org/10.1016/j.ejca.2014.04.026openalex-snapshot
Cytokine regulation by epidermal growth factor receptor inhibitors and epidermal growth factor receptor inhibitor associated skin toxicity in cancer patients
inferred← citeshttps://doi.org/10.1016/j.ejca.2015.11.022openalex-snapshot
Dosing to rash? – The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash
inferred← citeshttps://doi.org/10.1016/j.ejon.2015.07.003openalex-snapshot
Monoclonal antibody-induced papulopustular rash: Clinical course, communication to health-care professionals and reactive measures as reported by patients
inferred← citeshttps://doi.org/10.1016/j.ejso.2006.01.007openalex-snapshot
Monoclonal antibodies in the treatment of lung cancer
inferred← citeshttps://doi.org/10.1016/j.esmoop.2024.102975openalex-snapshot
Association between skin toxicity and efficacy of necitumumab in squamous non-small-cell lung cancer: a pooled analysis of two randomized clinical trials-SQUIRE and JFCM
inferred← citeshttps://doi.org/10.1016/j.esmoop.2026.107775openalex-snapshot
Anti-EGFR-based maintenance versus stop and go in patients with left-sided, non-MSI-H, RAS/BRAF-wt metastatic colorectal cancer: individual patient data pooled analysis
inferred← citeshttps://doi.org/10.1016/j.farma.2010.10.004openalex-snapshot
Toxicidad cutánea asociada a cetuximab en cáncer colorrectal metastásico
inferred← citeshttps://doi.org/10.1016/j.farmae.2010.10.001openalex-snapshot
Cutaneous Toxicity Associated With Cetuximab Treatment in Metastatic Colorectal Cancer
inferred← citeshttps://doi.org/10.1016/j.gamo.2015.12.010openalex-snapshot
Manejo y prevención de efectos secundarios al empleo de un anticuerpo monoclonal inhibidor de la señal de los receptores del factor de crecimiento epidérmico
inferred← citeshttps://doi.org/10.1016/j.gcb.2009.02.008openalex-snapshot
Biothérapies ciblées en cancérologie digestive : prise en charge de leurs effets secondaires
inferred← citeshttps://doi.org/10.1016/j.isci.2023.106089openalex-snapshot
CAR-T Cells Targeting HLA-G as Potent Therapeutic Strategy for EGFR Mutated and Overexpressed Oral Cancer
inferred← citeshttps://doi.org/10.1016/j.jaad.2006.04.062openalex-snapshot
Description and management of cutaneous side effects during cetuximab or erlotinib treatments: A prospective study of 30 patients
inferred← citeshttps://doi.org/10.1016/j.jaad.2006.06.034openalex-snapshot
Treatment of gefitinib-associated folliculitis
inferred← citeshttps://doi.org/10.1016/j.jaad.2006.09.005openalex-snapshot
Cutaneous side effects of epidermal growth factor receptor inhibitors: Clinical presentation, pathogenesis, and management
inferred← citeshttps://doi.org/10.1016/j.jaad.2008.01.001openalex-snapshot
Chemotherapeutic agents and the skin: An update
inferred← citeshttps://doi.org/10.1016/j.jaad.2008.07.057openalex-snapshot
Folliculitis-perifolliculitis related to erlotinib therapy spares previously irradiated skin
inferred← citeshttps://doi.org/10.1016/j.jaad.2009.03.046openalex-snapshot
A prospective randomized trial of topical pimecrolimus for cetuximab-associated acne-like eruption
inferred← citeshttps://doi.org/10.1016/j.jaad.2013.06.038openalex-snapshot
Pruritus in patients treated with targeted cancer therapies: Systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.jaad.2013.12.013openalex-snapshot
The spectrum of oculocutaneous disease
inferred← citeshttps://doi.org/10.1016/j.jaad.2013.12.019openalex-snapshot
The spectrum of oculocutaneous disease
inferred← citeshttps://doi.org/10.1016/j.jaad.2014.07.032openalex-snapshot
Cutaneous adverse effects of targeted therapies
inferred← citeshttps://doi.org/10.1016/j.jaad.2014.07.033openalex-snapshot
Cutaneous adverse effects of targeted therapies
inferred← citeshttps://doi.org/10.1016/j.jaad.2018.03.055openalex-snapshot
Hair disorders in patients with cancer
inferred← citeshttps://doi.org/10.1016/j.jaad.2019.06.1310openalex-snapshot
Increased infection rates associated with tetracycline therapy given for epidermal growth factor receptor inhibitor (EGFRI)-associated acneiform eruption: A retrospective study of data from two cancer centers
inferred← citeshttps://doi.org/10.1016/j.jaad.2019.12.031openalex-snapshot
Cutaneous eruptions from ibrutinib resembling epidermal growth factor receptor inhibitor–induced dermatologic adverse events
inferred← citeshttps://doi.org/10.1016/j.jconrel.2012.05.035openalex-snapshot
Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases
inferred← citeshttps://doi.org/10.1016/j.jconrel.2017.01.006openalex-snapshot
Longitudinal monitoring of skin accumulation of nanocarriers and biologicals with fiber optic near infrared fluorescence spectroscopy (FONIRS)
inferred← citeshttps://doi.org/10.1016/j.jdcr.2023.01.038openalex-snapshot
Osimertinib-associated erythema dyschromicum perstans–like eruption: A case series
inferred← citeshttps://doi.org/10.1016/j.jdermsci.2012.05.008openalex-snapshot
Indirubin, an acting component of indigo naturalis, inhibits EGFR activation and EGF-induced CDC25B gene expression in epidermal keratinocytes
inferred← citeshttps://doi.org/10.1016/j.jdermsci.2024.08.003openalex-snapshot
Staphylococcus epidermidis augments human β-defensin-3 synthesis through the transforming growth factor alpha-epidermal growth factor receptor cascade
inferred← citeshttps://doi.org/10.1016/j.jid.2022.04.026openalex-snapshot
Prophylactic Effect of Nitric Oxide Donors on Rat Models of EGFR Inhibitor‒Induced Cutaneous Toxicities
inferred← citeshttps://doi.org/10.1016/j.jpain.2023.11.018openalex-snapshot
EGFR Tyrosine Kinase Inhibitor Lazertinib Activates a Subset of Mouse Sensory Neurons Via TRPA1
inferred← citeshttps://doi.org/10.1016/j.jpainsymman.2006.07.006openalex-snapshot
Efficacy of Pregabalin in the Management of Cetuximab-Related Itch
inferred← citeshttps://doi.org/10.1016/j.lpm.2007.05.024openalex-snapshot
Effets secondaires dermatologiques des inhibiteurs de l’EGFR
inferred← citeshttps://doi.org/10.1016/j.lungcan.2015.03.019openalex-snapshot
Randomized, open-label trial evaluating the preventive effect of tetracycline on afatinib induced-skin toxicities in non-small cell lung cancer patients
inferred← citeshttps://doi.org/10.1016/j.med.2017.04.007openalex-snapshot
Nuevos fármacos en oncología: efectos secundarios cutáneos y su manejo
inferred← citeshttps://doi.org/10.1016/j.oraloncology.2011.10.019openalex-snapshot
Management of dermatitis in patients with locally advanced squamous cell carcinoma of the head and neck receiving cetuximab and radiotherapy
inferred← citeshttps://doi.org/10.1016/j.oraloncology.2012.02.008openalex-snapshot
Dermatitis associated with cetuximab and radiotherapy: The potential benefit with recombinant human epidermal growth factor and a concern regarding the use of steroids
inferred← citeshttps://doi.org/10.1016/j.patbio.2012.05.009openalex-snapshot
Thérapies anticancéreuses ciblées : vers une nouvelle toxicologie ?
inferred← citeshttps://doi.org/10.1016/j.pdpdt.2022.102994openalex-snapshot
5-aminolevulinic acid-mediated photodynamic therapy (ALA-PDT) for acneform rash induced by erlotinib: A case report
inferred← citeshttps://doi.org/10.1016/j.radonc.2008.09.018openalex-snapshot
Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer
inferred← citeshttps://doi.org/10.1016/j.rce.2011.05.018openalex-snapshot
Pulpitis seca y fisuras en los dedos de las manos en pacientes que reciben tratamiento combinado para hepatitis C
inferred← citeshttps://doi.org/10.1016/j.resinv.2017.11.009openalex-snapshot
Clinical impact of minocycline on afatinib-related rash in patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations
inferred← citeshttps://doi.org/10.1016/j.soncn.2006.08.003openalex-snapshot
Nursing Care of Patients Receiving Chemotherapy for Metastatic Colorectal Cancer: Implications of the Treatment Continuum Concept
inferred← citeshttps://doi.org/10.1016/j.soncn.2007.10.005openalex-snapshot
Managing Treatment Side Effects in Advanced Breast Cancer
inferred← citeshttps://doi.org/10.1016/j.suponc.2010.09.003openalex-snapshot
A Prospective Crossover Pilot Study to Evaluate the Use of a Topical Wound Gel in Patients with Cutaneous Toxicity Caused by Epidermal Growth Factor Receptor Inhibitors
inferred← citeshttps://doi.org/10.1016/j.tox.2024.154018openalex-snapshot
EGFR-TKIs induce acneiform rash and xerosis via Caspase-3/GSDME-mediated pyroptosis of keratinocytes and sebocytes
inferred← citeshttps://doi.org/10.1016/s0001-7310(06)73407-xopenalex-snapshot
Efectos cutáneos de los inhibidores del receptor del factor de crecimiento epidérmico
inferred← citeshttps://doi.org/10.1016/s0001-7310(06)73451-2openalex-snapshot
Tratamiento de la erupción acneiforme por inhibidores del factor de crecimiento epidérmico con tetraciclinas orales
inferred← citeshttps://doi.org/10.1016/s0001-7310(07)70155-2openalex-snapshot
Erupción acneiforme aguda secundaria a cetuximab con buena respuesta a metronidazol
inferred← citeshttps://doi.org/10.1016/s0001-7310(08)74615-5openalex-snapshot
Efectos cutáneos adversos causados por erlotinib
inferred← citeshttps://doi.org/10.1016/s0151-9638(06)71093-6openalex-snapshot
Aspects cliniques et prise en charge des effets secondaires cutanés des inhibiteurs du récepteur à l’EGF
inferred← citeshttps://doi.org/10.1016/s0151-9638(08)70093-0openalex-snapshot
Effets secondaires cutanés des nouvelles molécules anticancéreuses : focus sur les molécules ciblant les récepteurs tyrosine kinase et le récepteur à l’EGF
inferred← citeshttps://doi.org/10.1016/s0151-9638(11)70079-5openalex-snapshot
Formes cliniques et classification de la rosacée
inferred← citeshttps://doi.org/10.1016/s0151-9638(11)70089-8openalex-snapshot
Clinical presentations and classification of rosacea
inferred← citeshttps://doi.org/10.1016/s0212-5382(09)70553-9openalex-snapshot
Tratamientos contra el cáncer: “armas inteligentes” que atacan el cáncer mediante novedosos mecanismos
inferred← citeshttps://doi.org/10.1016/s0213-9251(08)70986-9openalex-snapshot
Erupción acneiforme por inhibidores del factor de crecimiento epidérmico
inferred← citeshttps://doi.org/10.1016/s0246-0319(13)65436-9openalex-snapshot
10.1016/s0246-0319(13)65436-9
inferred← citeshttps://doi.org/10.1016/s0305-7372(10)70003-7openalex-snapshot
Panitumumab – an effective long-term treatment for patients with metastatic colorectal cancer and wild-type KRAS status
inferred← citeshttps://doi.org/10.1016/s0959-8049(09)70044-9openalex-snapshot
Skin toxicities of targeted therapies
inferred← citeshttps://doi.org/10.1016/s1470-2045(10)70278-3openalex-snapshot
First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study
inferred← citeshttps://doi.org/10.1016/s1470-2045(14)71133-7openalex-snapshot
Nail toxicities induced by systemic anticancer treatments
inferred← citeshttps://doi.org/10.1016/s1470-2045(15)00021-2openalex-snapshot
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
inferred← citeshttps://doi.org/10.1016/s1470-2045(15)70046-xopenalex-snapshot
Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study
inferred← citeshttps://doi.org/10.1016/s1548-5315(11)70076-6openalex-snapshot
Managing follicular rash related to chemotherapy and monoclonal antibodies
showing the first 200 of 541 · page through all 541
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.